Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Hematologic Neoplasms 2Cardiotoxicity 2Sarcoma 1Prostatic Neoplasms 1Lymphoma 1Heart Failure 1Cardiovascular Abnormalities 1Breast Neoplasms, Male 1

Interventions

Control Groups 2Atorvastatin 2sacubitril and valsartan sodium hydrate drug combination 1pertuzumab 1nicotinamide-beta-riboside 1empagliflozin 1dapagliflozin 1candesartan 1Trastuzumab 1Sodium Chloride 1Simendan 1Pyruvic Acid 1Population Groups 1Ogivri 1Metoprolol 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Eplerenone 1Carvedilol 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Heart Failure × Carvedilol × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡